UBS Group’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $29.2M | Sell |
1,624,415
-608,044
| -27% | -$11.5M | ﹤0.01% | 2288 |
|
|
2026
Q1 | $48.6M | Buy |
2,232,459
+173,758
| +8% | +$3.36M | 0.01% | 1673 |
|
|
2025
Q4 | $44.3M | Buy |
2,058,701
+68,193
| +3% | +$1.44M | 0.01% | 1736 |
|
|
2025
Q3 | $38.4M | Buy |
1,990,508
+1,489,424
| +297% | +$26.6M | 0.01% | 1896 |
|
|
2025
Q2 | $8.57M | Sell |
501,084
-945,374
| -65% | -$40.3M | ﹤0.01% | 3249 |
|
|
2025
Q1 | $92.3M | Sell |
1,446,458
-33,540
| -2% | -$3.53M | 0.02% | 988 |
|
|
2024
Q4 | $180M | Buy |
1,479,998
+1,115,826
| +306% | +$137M | 0.03% | 565 |
|
|
2024
Q3 | $45.5M | Buy |
364,172
+13,408
| +4% | +$1.85M | 0.01% | 1212 |
|
|
2024
Q2 | $55.4M | Buy |
350,764
+73,574
| +27% | +$9.45M | 0.01% | 975 |
|
|
2024
Q1 | $35.9M | Buy |
277,190
+914
| +0.3% | +$112K | 0.01% | 1263 |
|
|
2023
Q4 | $26.6M | Buy |
276,276
+48,405
| +21% | +$4.64M | 0.01% | 1386 |
|
|
2023
Q3 | $27.6M | Buy |
227,871
+11,531
| +5% | +$1.3M | 0.01% | 1243 |
|
|
2023
Q2 | $24.8M | Buy |
216,340
+21,918
| +11% | +$2.83M | 0.01% | 1287 |
|
|
2023
Q1 | $26.8M | Buy |
194,422
+31,742
| +20% | +$4.12M | 0.01% | 1174 |
|
|
2022
Q4 | $21.1M | Buy |
162,680
+91,942
| +130% | +$10.7M | 0.01% | 1369 |
|
|
2022
Q3 | $7.82M | Sell |
70,738
-46,200
| -40% | -$4.66M | ﹤0.01% | 1989 |
|
|
2022
Q2 | $8.77M | Sell |
116,938
-35,935
| -24% | -$2.64M | ﹤0.01% | 1911 |
|
|
2022
Q1 | $11.9M | Buy |
152,873
+90,229
| +144% | +$6.91M | ﹤0.01% | 1802 |
|
|
2021
Q4 | $5.64M | Buy |
62,644
+15,913
| +34% | +$1.36M | ﹤0.01% | 2697 |
|
|
2021
Q3 | $4.32M | Buy |
46,731
+12,796
| +38% | +$986K | ﹤0.01% | 2828 |
|
|
2021
Q2 | $2.64M | Sell |
33,935
-53,265
| -61% | -$4.04M | ﹤0.01% | 3310 |
|
|
2021
Q1 | $6.5M | Buy |
87,200
+15,450
| +22% | +$1.43M | ﹤0.01% | 2336 |
|
|
2020
Q4 | $12.2M | Buy |
71,750
+4,895
| +7% | +$725K | ﹤0.01% | 1698 |
|
|
2020
Q3 | $9.39M | Buy |
66,855
+1,990
| +3% | +$302K | ﹤0.01% | 1685 |
|
|
2020
Q2 | $10.4M | Sell |
64,865
-18,799
| -22% | -$2.56M | ﹤0.01% | 1466 |
|
|
2020
Q1 | $8.18M | Sell |
83,664
-3,315
| -4% | -$379K | ﹤0.01% | 1551 |
|
|
2019
Q4 | $11.2M | Sell |
86,979
-108,252
| -55% | -$10.9M | ﹤0.01% | 1852 |
|
|
2019
Q3 | $14.7M | Buy |
195,231
+85,870
| +79% | +$10.1M | 0.01% | 1461 |
|
|
2019
Q2 | $16.6M | Buy |
109,361
+28,958
| +36% | +$3.52M | 0.01% | 1345 |
|
|
2019
Q1 | $9.58M | Sell |
80,403
-4,472
| -5% | -$575K | ﹤0.01% | 1708 |
|
|
2018
Q4 | $9.26M | Buy |
84,875
+22,929
| +37% | +$2.87M | ﹤0.01% | 1634 |
|
|
2018
Q3 | $10M | Sell |
61,946
-28,870
| -32% | -$3.95M | ﹤0.01% | 1781 |
|
|
2018
Q2 | $12M | Sell |
90,816
-17,148
| -16% | -$1.62M | 0.01% | 1585 |
|
|
2018
Q1 | $8M | Buy |
107,964
+29,550
| +38% | +$1.97M | ﹤0.01% | 1894 |
|
|
2017
Q4 | $4.36M | Sell |
78,414
-56,400
| -42% | -$2.99M | ﹤0.01% | 2489 |
|
|
2017
Q3 | $6.12M | Buy |
134,814
+35,317
| +35% | +$1.41M | ﹤0.01% | 2029 |
|
|
2017
Q2 | $3.35M | Buy |
99,497
+18,053
| +22% | +$588K | ﹤0.01% | 2503 |
|
|
2017
Q1 | $2.41M | Sell |
81,444
-11,529
| -12% | -$357K | ﹤0.01% | 2766 |
|
|
2016
Q4 | $2.55M | Sell |
92,973
-21,167
| -19% | -$850K | ﹤0.01% | 2693 |
|
|
2016
Q3 | $7.01M | Sell |
114,140
-332,947
| -74% | -$10.1M | ﹤0.01% | 1713 |
|
|
2016
Q2 | $8.53M | Buy |
447,087
+348,081
| +352% | +$6.45M | 0.01% | 1506 |
|
|
2016
Q1 | $1.93M | Sell |
99,006
-88,019
| -47% | -$1.54M | ﹤0.01% | 2698 |
|
|
2015
Q4 | $7.22M | Buy |
187,025
+96,871
| +107% | +$3.14M | ﹤0.01% | 1665 |
|
|
2015
Q3 | $2.9M | Sell |
90,154
-34,824
| -28% | -$1.18M | ﹤0.01% | 2415 |
|
|
2015
Q2 | $3.8M | Buy |
124,978
+42,665
| +52% | +$872K | ﹤0.01% | 2351 |
|
|
2015
Q1 | $1.09M | Sell |
82,313
-8,104
| -9% | -$108K | ﹤0.01% | 3490 |
|
|
2014
Q4 | $1.31M | Buy |
+90,417
| New | +$1.53M | ﹤0.01% | 3343 |
|
Other funds holding SRPT
EAM
UBS Group's SRPT Position: Q2 2026 in Review
UBS Group reduced its Sarepta Therapeutics (SRPT) stake by 27% in Q2 2026, selling an estimated $11.5M and leaving 1,624,415 shares worth $29.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2288.
UBS Group first reported a position in SRPT in Q4 2014 and has held it in 47 quarters since. The position peaked at $180M in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- UBS Group held 1,624,415 shares of Sarepta Therapeutics worth $29.2M as of Q2 2026.
- UBS Group sold 608,044 Sarepta Therapeutics shares in Q2 2026, an estimated $11.5M.
- Sarepta Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2288 holding.
- UBS Group first reported a position in Sarepta Therapeutics in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Sarepta Therapeutics position peaked at $180M in Q4 2024.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.